Results 151 to 160 of about 15,283 (290)
In defence of the drug, two hearts, one profession: Reintegrating medicines expertise and patient-centred care in pharmacy's professional identity. [PDF]
Davies NM.
europepmc +1 more source
Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee +20 more
wiley +1 more source
Epileptic drop attacks: More than just atonic seizures
Abstract “Drop attacks” are not officially defined by the International League Against Epilepsy. Seizures are characterized by a sudden loss of control over the trunk and posture, leading to falls and injuries, and resolving within a few seconds. Accurately diagnosing the type of seizure is usually difficult due to limitations in clinical documentation
Tomonori Ono +3 more
wiley +1 more source
Abstract Objective Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in otherwise healthy patients with epilepsy; about 70% occurs during sleep, and nearly 90% of patients are found prone (face‐down). Following a nocturnal seizure, terminal apnea occurs between 2.5 and 10.8 min postictally (median ~ 5 min), defining a narrow but
Jong Woo Lee +6 more
wiley +1 more source
Retraction Note: Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways. [PDF]
Emam SE +9 more
europepmc +1 more source
Impact of vigabatrin on risk of relapse of infantile spasms
Abstract Objective Vigabatrin is an effective treatment for infantile epileptic spasms syndrome (IESS), but relapse remains a clinical challenge. The ideal dose and duration of treatment after response are unknown. We set out to identify treatment‐related predictors of IESS relapse after initial vigabatrin response. Methods We conducted a retrospective
Yaretson I. Carmenate +5 more
wiley +1 more source
Physiologically Based Biopharmaceutics Modelling-Best Scientific Practices to Define Drug Product Performance, Latest Regulatory and Industry Perspectives: Workshop Summary Report. [PDF]
McAllister M +23 more
europepmc +1 more source

